Cargando…

Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States

BACKGROUND: Asthma is the most common inflammatory lung disease in the United States. Since 2015, biologic therapies have provided targeted treatment for patients with severe asthma. OBJECTIVE: To evaluate the trends for in-hospital outcomes of asthma before (2012-2014) and after (2016-2018) the int...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Hye-Rim, Hernandez-Con, Pilar, Heo, Ji Haeng, Wilson, Debbie L, Blake, Kathryn V, Lang, Jason E, Park, Haesuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388017/
https://www.ncbi.nlm.nih.gov/pubmed/37404074
http://dx.doi.org/10.18553/jmcp.2023.29.7.721
_version_ 1785082015814516736
author Kang, Hye-Rim
Hernandez-Con, Pilar
Heo, Ji Haeng
Wilson, Debbie L
Blake, Kathryn V
Lang, Jason E
Park, Haesuk
author_facet Kang, Hye-Rim
Hernandez-Con, Pilar
Heo, Ji Haeng
Wilson, Debbie L
Blake, Kathryn V
Lang, Jason E
Park, Haesuk
author_sort Kang, Hye-Rim
collection PubMed
description BACKGROUND: Asthma is the most common inflammatory lung disease in the United States. Since 2015, biologic therapies have provided targeted treatment for patients with severe asthma. OBJECTIVE: To evaluate the trends for in-hospital outcomes of asthma before (2012-2014) and after (2016-2018) the introduction of biologic therapies for asthma. METHODS: We conducted a nationwide cross-sectional analysis of patients aged 2 years or older who were hospitalized for asthma between 2012 and 2018 using data from the Nationwide Readmissions Database. Outcomes included rates of asthma hospital admission and asthma-related 30-day readmission, hospital length of stay, hospital costs, and inpatient mortality. Generalized linear models assessed trends in rates of asthma admission and readmission, length of stay, costs, and mortality quarterly during 2012-2014 and 2016-2018. RESULTS: Among 691,537 asthma-related admissions, quarterly asthma admission rates significantly decreased (−0.90%, 95% CI = −1.46% to − 0.34%; P = 0.002) during 2016-2018, mainly among adults, but not during 2012-2014. Quarterly assessed readmission rates decreased by 2.40% (−2.85% to −1.96%; P < 0.0001) during 2012-2014 and by 2.12% (−2.74% to − 1.50%; P < 0.0001) during 2016-2018. Mean length of stay for asthma admissions decreased quarterly by 0.44% (−0.49% to − 0.38%; P < 0.0001) during 2012-2014 and by 0.27% (−0.34% to − 0.20%; P < 0.0001) during 2016-2018. Quarterly hospital costs for admissions were unchanged during 2012-2014 but increased by 0.28% (0.21% to 0.35%; P < 0.0001) during 2016-2018. There were no significant trends in inpatient mortality during 2012-2014 and 2016-2018. CONCLUSIONS: After the introduction of new biologics for severe asthma in 2015, asthma-related hospital admissions decreased significantly, whereas hospital costs increased. Asthma-related 30-day readmission rates and length of stay for asthma admissions continuously decreased, whereas inpatient mortality rates remained stable.
format Online
Article
Text
id pubmed-10388017
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103880172023-07-31 Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States Kang, Hye-Rim Hernandez-Con, Pilar Heo, Ji Haeng Wilson, Debbie L Blake, Kathryn V Lang, Jason E Park, Haesuk J Manag Care Spec Pharm Research BACKGROUND: Asthma is the most common inflammatory lung disease in the United States. Since 2015, biologic therapies have provided targeted treatment for patients with severe asthma. OBJECTIVE: To evaluate the trends for in-hospital outcomes of asthma before (2012-2014) and after (2016-2018) the introduction of biologic therapies for asthma. METHODS: We conducted a nationwide cross-sectional analysis of patients aged 2 years or older who were hospitalized for asthma between 2012 and 2018 using data from the Nationwide Readmissions Database. Outcomes included rates of asthma hospital admission and asthma-related 30-day readmission, hospital length of stay, hospital costs, and inpatient mortality. Generalized linear models assessed trends in rates of asthma admission and readmission, length of stay, costs, and mortality quarterly during 2012-2014 and 2016-2018. RESULTS: Among 691,537 asthma-related admissions, quarterly asthma admission rates significantly decreased (−0.90%, 95% CI = −1.46% to − 0.34%; P = 0.002) during 2016-2018, mainly among adults, but not during 2012-2014. Quarterly assessed readmission rates decreased by 2.40% (−2.85% to −1.96%; P < 0.0001) during 2012-2014 and by 2.12% (−2.74% to − 1.50%; P < 0.0001) during 2016-2018. Mean length of stay for asthma admissions decreased quarterly by 0.44% (−0.49% to − 0.38%; P < 0.0001) during 2012-2014 and by 0.27% (−0.34% to − 0.20%; P < 0.0001) during 2016-2018. Quarterly hospital costs for admissions were unchanged during 2012-2014 but increased by 0.28% (0.21% to 0.35%; P < 0.0001) during 2016-2018. There were no significant trends in inpatient mortality during 2012-2014 and 2016-2018. CONCLUSIONS: After the introduction of new biologics for severe asthma in 2015, asthma-related hospital admissions decreased significantly, whereas hospital costs increased. Asthma-related 30-day readmission rates and length of stay for asthma admissions continuously decreased, whereas inpatient mortality rates remained stable. Academy of Managed Care Pharmacy 2023-07 /pmc/articles/PMC10388017/ /pubmed/37404074 http://dx.doi.org/10.18553/jmcp.2023.29.7.721 Text en Copyright © 2023, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Kang, Hye-Rim
Hernandez-Con, Pilar
Heo, Ji Haeng
Wilson, Debbie L
Blake, Kathryn V
Lang, Jason E
Park, Haesuk
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States
title Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States
title_full Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States
title_fullStr Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States
title_full_unstemmed Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States
title_short Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States
title_sort nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: a cross-sectional study in the united states
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388017/
https://www.ncbi.nlm.nih.gov/pubmed/37404074
http://dx.doi.org/10.18553/jmcp.2023.29.7.721
work_keys_str_mv AT kanghyerim nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates
AT hernandezconpilar nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates
AT heojihaeng nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates
AT wilsondebbiel nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates
AT blakekathrynv nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates
AT langjasone nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates
AT parkhaesuk nationwidetrendsinhospitalizationmedicalcostsandmortalityforasthmaafterintroductionofbiologicsacrosssectionalstudyintheunitedstates